Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,884,913
  • Shares Outstanding, K 62,270
  • Annual Sales, $ 20,530 K
  • Annual Income, $ -133,750 K
  • 60-Month Beta 2.09
  • Price/Sales 100.63
  • Price/Cash Flow N/A
  • Price/Book 4.29
Trade EDIT with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.64
  • Number of Estimates 6
  • High Estimate -0.49
  • Low Estimate -0.69
  • Prior Year -0.66
  • Growth Rate Est. (year over year) +3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.01 +12.07%
on 10/02/20
35.06 -13.66%
on 10/14/20
-2.07 (-6.40%)
since 09/21/20
3-Month
27.01 +12.07%
on 10/02/20
39.96 -24.25%
on 08/06/20
-0.05 (-0.16%)
since 07/21/20
52-Week
14.01 +116.06%
on 03/16/20
39.96 -24.25%
on 08/06/20
+9.81 (+47.95%)
since 10/21/19

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher

TMO : 468.76 (+0.75%)
VRTX : 211.38 (-1.47%)
EBS : 93.04 (-3.79%)
EDIT : 30.27 (-8.77%)
CLLS : 17.08 (-5.53%)
Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

TMO : 468.76 (+0.75%)
VRTX : 211.38 (-1.47%)
EBS : 93.04 (-3.79%)
EDIT : 30.27 (-8.77%)
CLLS : 17.08 (-5.53%)
NTLA : 23.49 (-3.53%)
CRSP : 92.22 (-13.57%)
NASDAQ Jumps 4%+ This Week, While S&P, Dow Rise Over 3%

NASDAQ Jumps 4%+ This Week, While S&P, Dow Rise Over 3%

AGYS : 25.64 (-4.11%)
NTLA : 23.49 (-3.53%)
EDIT : 30.27 (-8.77%)
CRSP : 92.22 (-13.57%)
SGMO : 10.37 (-2.17%)
HEAR : 17.98 (-3.95%)
JPM : 99.37 (-1.00%)
C : 43.01 (-1.17%)
BAC : 24.05 (-0.37%)
GS : 202.91 (-2.46%)
MS : 50.38 (-2.12%)
4 Modern Healthcare Stocks Google is Investing In

Google (GOOG) is a tech conglomerate. Its Search business gives it special insight into future trends. So, it's interesting that it's aggressively investing in so many health care companies. Editas (EDIT),...

GOOG : 1,593.31 (+2.40%)
GOOGL : 1,585.99 (+2.25%)
EDIT : 30.27 (-8.77%)
AMWL : 32.67 (-0.43%)
ONEM : 31.59 (+1.58%)
Amgen Down on Unsatisfactory Heart Failure Drug Study Results

Amgen (AMGN) with partners post top-line data from the phase III GALACTIC-HF study on omecamtiv mecarbil, which is being evaluated for heart failure with reduced ejection fraction. Stock falls.

AMGN : 228.97 (-0.92%)
AVEO : 5.64 (-3.26%)
CYTK : 15.70 (-3.44%)
EDIT : 30.27 (-8.77%)
BioMarin (BMRN) Gets FDA Approval for Higher Dose of Palynziq

The FDA approves higher dose (60 mg) of BioMarin's (BMRN) Phenylketonuria drug Palynziq injection. The regulatory nod includes the addition of longer-term efficacy data on Palynziq's label.

RDY : 67.61 (-1.27%)
BMRN : 77.50 (-0.53%)
AVEO : 5.64 (-3.26%)
EDIT : 30.27 (-8.77%)
Big October Winners: CRISPR, Alteryx, NVIDIA, Quidel

Two women will share the Nobel prize for a gene editing technology that will change the world.

NVDA : 540.99 (-0.88%)
QDEL : 241.98 (-3.01%)
EDIT : 30.27 (-8.77%)
TTD : 624.67 (+2.02%)
NTLA : 23.49 (-3.53%)
CRSP : 92.22 (-13.57%)
AYX : 137.22 (-1.66%)
Editas Medicine to Participate in Upcoming Investor Conference

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conference:

EDIT : 30.27 (-8.77%)
CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease.

VRTX : 211.38 (-1.47%)
EDIT : 30.27 (-8.77%)
NTLA : 23.49 (-3.53%)
CRSP : 92.22 (-13.57%)
KromaTiD Announces the Appointment of Vic Myer, PhD to its Board of Directors

, /PRNewswire/ -- KromaTiD, Inc. today announced the appointment of Vic Myer to its Board of Directors. Dr. Myer joins KromaTiD's Board with extensive experience in technology, R&D and pharmaceutical...

EDIT : 30.27 (-8.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 33.32
1st Resistance Point 31.80
Last Price 30.27
1st Support Level 29.30
2nd Support Level 28.32

See More

52-Week High 39.96
Last Price 30.27
Fibonacci 61.8% 30.05
Fibonacci 50% 26.99
Fibonacci 38.2% 23.92
52-Week Low 14.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar